SCHEMBL3107614

SCHEMBL3107614

CCNC(=O)c1ccc(N)cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.54
▸ THRB P10828 1/20 0.54
▸ RECQL P46063 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ JAK2 O60674 1/20 0.54
▸ TYK2 P29597 1/20 0.54
▸ CHRM2 P08172 1/20 0.49
▸ CHRM3 P20309 1/20 0.49
▸ MAOA P21397 1/20 0.49
▸ HTR2C P28335 1/20 0.49
▸ CHRNA4 P43681 1/20 0.49
▸ HTR3A P46098 1/20 0.49
▸ KCNH2 Q12809 1/20 0.49
▸ HRH3 Q9Y5N1 1/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ MAPT P10636 2/20 0.49
▸ LMNA P02545 1/20 0.48
▸ HPGD P15428 3/20 0.47
▸ CRBN Q96SW2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6983716 0.87 POLB (0.72) POLBTHRBRECQLTDP1L3MBTL1
SCHEMBL7224774 0.87 P2RX7 (0.57) POLBTHRBRECQLTDP1L3MBTL1
SCHEMBL11120428 0.83 LMNA (0.43) POLBTHRBRECQLTDP1L3MBTL1
SCHEMBL4148502 0.83 POLB (0.76) POLBTHRBRECQLTDP1L3MBTL1
SCHEMBL14547921 0.83 KDM4E (0.57) POLBTHRBRECQLTDP1L3MBTL1
SCHEMBL19823877 0.82 MAPT (0.70) POLBTHRBRECQLTDP1L3MBTL1
SCHEMBL3106472 0.81 CRBN (0.46) JAK2MAOAMAPTLMNAHPGD
SCHEMBL12121109 0.81 HPGD (0.68) POLBTHRBRECQLTDP1L3MBTL1
SCHEMBL7970021 0.81 JAK2 (0.58) POLBTHRBRECQLTDP1L3MBTL1
SCHEMBL29748463 0.81 JAK2 (0.58) POLBTHRBRECQLTDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2298747-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2011-03-23 — — EP disclosed
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 — — US disclosed
WO-2010001946-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF アステラス製薬株式会社 (JP) 2010-01-07 — — WO disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 — — US disclosed
EP-1867331-A1 TRIAZOLE DERIVATIVE AND THE USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-12-19 — — EP disclosed
WO-2007042299-A1 PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS GLAXO GROUP LIMITED (GB) 2007-04-19 — — WO disclosed
US-4093734-A ANTIULCER AGENTS, ANTIEMETICS, ANTICONVULSANTS BOEHRINGER INGELHEIM GMBH (DT) 1978-06-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105253-A1 Triazole Derivative and Use Thereof F2R, HRH4, F2RL3 POLB 3558/4885THRB 171/4885RECQL 3116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback